| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0021-9150(81)90103-9 |
| P698 | PubMed publication ID | 7470205 |
| P2093 | author name string | E Marth | |
| G M Kostner | |||
| G Cazzolato | |||
| P Avogaro | |||
| G Bittolo-Bon | |||
| G B Qunici | |||
| P433 | issue | 1-2 | |
| P921 | main subject | myocardial infarction | Q12152 |
| P304 | page(s) | 51-61 | |
| P577 | publication date | 1981-01-01 | |
| P1433 | published in | Atherosclerosis | Q4813570 |
| P1476 | title | Lipoprotein Lp(a) and the risk for myocardial infarction | |
| P478 | volume | 38 |
| Q67902719 | A Comparison of Commercial Kits for the Measurement of Lipoprotein(a) |
| Q52425625 | A structural assessment of the apo[a] protein of human lipoprotein[a] |
| Q37039943 | Abnormalities of cholesterol metabolism in diabetes |
| Q45876542 | Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo |
| Q33612119 | Apolipoprotein (a) concentrations and susceptibility to coronary artery disease in patients with peripheral vascular disease |
| Q53947195 | Apolipoprotein (a) levels in type 1 and type 2 diabetes mellitus |
| Q48801311 | Apolipoprotein (a): a comparison of isoforms identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis or by sodium dodecyl sulfate-agarose gel electrophoresis |
| Q39606704 | Apolipoprotein polymorphism and multifactorial hyperlipidaemia |
| Q92483764 | Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia |
| Q35599857 | Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease |
| Q72804309 | Apolipoproteins (A-I, A-II, B), Lp(a) lipoprotein and lecithin: Cholesterol acyltransferase activity in diabetes mellitus |
| Q41346637 | Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease |
| Q41828322 | Apoprotein B of lipoprotein(a) of human plasma |
| Q44620563 | Apoprotein(a) phenotypes and plasma lipoprotein(a) concentration in patients with diabetes mellitus |
| Q57187342 | Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials |
| Q72911913 | Binding of LP(a) to the low density lipoprotein receptor of human fibroblasts |
| Q41732277 | Biogenesis of lipoprotein(a) in human and animal hepatocytes |
| Q43953838 | Blood pressure, serum lipids, and fatty acids in populations on a lake-fish diet or on a vegetarian diet in Tanzania |
| Q42860196 | Characterization of the enzyme activity of human plasma lipoprotein (a) using synthetic peptide substrates |
| Q72041330 | Comparison of a new immunoturbidometric assay of human serum lipoprotein (a) to the ELISA and the IRMA methods |
| Q72005557 | Comparison of effects of N-3 to N-6 fatty acids on serum level of lipoprotein(a) in patients with coronary artery disease |
| Q41594265 | Control of Hep G2-cell triacylglycerol and apolipoprotein B synthesis and secretion by polyunsaturated non-esterified fatty acids and insulin |
| Q78078786 | Correlates of lipoprotein(a) levels in a biracial cohort of young girls: the NHLBI Growth and Health Study |
| Q64930565 | Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). |
| Q54430137 | Determinants of risk factors of atherosclerosis in the postinfarction period: the Tallinn MI study. |
| Q67907131 | Dietary fish oil lowers lipoprotein(a) in primary hypertriglyceridemia |
| Q44297697 | Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability. |
| Q41153703 | Does lipoprotein(a) (Lp(a)) compete with plasminogen in human atherosclerotic lesions and thrombi? |
| Q70806845 | Double labeling of lipoprotein receptors in fibroblast cell surface replicas |
| Q54440502 | Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia. |
| Q40958594 | Effect of tranexamic acid and delta-aminovaleric acid on lipoprotein(a) metabolism in transgenic mice |
| Q72391916 | Effects of a lacto-ovo vegetarian diet on serum concentrations of cholesterol, triglyceride, HDL-C, HDL2-C, HDL3-C, apoprotein-B, and Lp(a) |
| Q43813835 | Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men. |
| Q35328774 | Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). |
| Q67902720 | Effects of dietary fish oil supplementation on platelet aggregability and platelet membrane fluidity in normolipemic subjects with and without high plasma Lp(a) concentrations |
| Q33719966 | Effects of exercise on lipoprotein(a). |
| Q51636953 | Effects of glyburide therapy on lipoproteins in non-insulin-dependent diabetes mellitus. |
| Q71434209 | Effects of growth hormone on serum lipids and lipoproteins: possible significance of increased peripheral conversion of thyroxine to triiodothyronine |
| Q73079062 | Effects of misoprostol on lipoprotein (a) levels of ovariectomized rats |
| Q57337242 | Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer |
| Q44157324 | Elevated endothelin levels in patients with hyperlipoproteinemia |
| Q74182500 | Elevated levels of lipoprotein(a) in women with preeclampsia |
| Q72630916 | Elevated lipoprotein (a) levels in primary nephrotic syndrome |
| Q37392489 | Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study |
| Q33888645 | Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a) |
| Q71694123 | Elevated serum Lp(a) concentration and the rare apo(a) phenotype in a patient with myocardial infarction |
| Q77643955 | Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: a transesophageal echocardiographic study |
| Q51574726 | Elevated serum lipoprotein(a) levels in young women with endometriosis. |
| Q67762199 | Elevation of factor VII activity and mass in coronary artery disease of varying severity |
| Q34786504 | Enigmatic role of lipoprotein(a) in cardiovascular disease |
| Q40802371 | Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease |
| Q43749764 | Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). population-based reference values in an area with low incidence of cardiovascular disease. |
| Q73102117 | Factors contributing to variation in lipoprotein (a) in Melbourne Anglo-Celtic population |
| Q72790235 | Familial Study on "Sinking pre-beta", the Lp(a) Lipoprotein, and its Relationship with Serum Lipids, Apolipoprotein A-I and B and Clinical Atherosclerosis |
| Q74595429 | Family history of early cardiovascular disease in children with moderate to severe hypercholesterolemia: relationship to lipoprotein (a) and low-density lipoprotein cholesterol levels |
| Q35187047 | Farnesoid X receptor represses hepatic human APOA gene expression |
| Q42610568 | Frequent occurrence of familial aggregations of high lipoprotein(a) levels associated with small apolipoprotein(a) isoforms |
| Q73267351 | Genetic determinants of atherosclerosis-related dyslipidemias and their clinical implications |
| Q41357121 | Genetics of the quantitative Lp(a) lipoprotein trait. I. Relation of LP(a) glycoprotein phenotypes to Lp(a) lipoprotein concentrations in plasma |
| Q41333582 | Genetics of the quantitative Lp(a) lipoprotein trait. II. Inheritance of Lp(a) glycoprotein phenotypes |
| Q35600471 | Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma |
| Q35831887 | Immunohistochemical distribution of lipoprotein epitopes in xanthomata from patients with familial hypercholesterolemia |
| Q44585477 | Immunosorbent for Selective Removal of Lipoprotein (a) from Human Plasma: In Vitro Study |
| Q52877795 | Immunoturbidimetric determination of lipoprotein(a): improvement in the measurement of turbid and triglyceride-rich samples |
| Q45309944 | Increased concentrations of lipoprotein(a), circadian rhythms and metabolic reactions evoked by acute myocardial infarction, associated with acute reactions in relation to large breakfasts |
| Q41283225 | Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout |
| Q47702951 | Influence of lipoprotein(a) plasma concentration on neointimal growth in a monkey model of vascular injury |
| Q71827307 | Influence of plasma lipoprotein(a) levels on coronary vasomotor response to acetylcholine |
| Q41289982 | Inhibitors for the In Vitro Assembly of Lp(a) |
| Q74106158 | LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group |
| Q73574560 | Levels of lipoprotein (a) in pulmonary arterial hypertension |
| Q34571133 | Lipolytic surface remnants of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein. A possible mechanism of atherogenesis? |
| Q41148759 | Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants |
| Q50936066 | Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. |
| Q30242031 | Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology |
| Q35626653 | Lipoprotein (a) concentrations as risk indicators for atherosclerosis |
| Q58421413 | Lipoprotein (a) does not influence hyperfibrinolysis in patients with liver cirrhosis |
| Q36731801 | Lipoprotein (a) measurements for clinical application |
| Q50949167 | Lipoprotein (a) serum levels in patients with hepatocarcinoma. |
| Q40964818 | Lipoprotein (a). |
| Q37853403 | Lipoprotein (a). Heterogeneity and biological relevance |
| Q39002143 | Lipoprotein (a): a historical appraisal |
| Q37033161 | Lipoprotein (a): impact by ethnicity and environmental and medical conditions |
| Q34020677 | Lipoprotein (a): structure, pathophysiology and clinical implications. |
| Q50998785 | Lipoprotein(a) and its correlates in Japanese and U.S. population samples. |
| Q24305939 | Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it |
| Q41197625 | Lipoprotein(a) enhances plasma clot lysis in vitro |
| Q72809757 | Lipoprotein(a) in patients treated by continuous ambulatory peritoneal dialysis |
| Q40937490 | Lipoprotein(a) in renal disease |
| Q35195920 | Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes |
| Q91684402 | Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction |
| Q36237559 | Lipoprotein(a): Cellular Effects and Molecular Mechanisms |
| Q37120738 | Lipoprotein(a): Nonhuman primate models |
| Q35746190 | Lipoprotein(a): an elusive cardiovascular risk factor |
| Q34658104 | Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events |
| Q67546736 | Lp(a) and the risk of coronary heart disease |
| Q24561687 | Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma |
| Q67901566 | Lp(a) lipoprotein in patients with arterial insufficiency of the lower extremities |
| Q44604661 | Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen |
| Q37858375 | Markers of Chlamydia pneumoniae and human cytomegalovirus infection in patients with chronic peripheral vascular disease and their relation to inflammation, endothelial dysfunction and changes in lipid metabolism |
| Q34547889 | Metabolic aspects of trans fatty acids |
| Q34265255 | Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis |
| Q33822162 | Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a) |
| Q36302760 | Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice |
| Q67897493 | Oxidation of lipoprotein Lp(a). A comparison with low-density lipoproteins |
| Q73245485 | Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels |
| Q52364965 | Plasma lipids and lipoproteins and essential hypertension. |
| Q33664574 | Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? |
| Q36731797 | Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study |
| Q40997572 | Procoagulant Properties of Atherosclerotic Aortasa |
| Q28344599 | Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype |
| Q72779344 | Protein composition of Lp(a) lipoprotein from human plasma |
| Q72799502 | Quantification of human serum lipoprotein Lp(a): zone immunoelectrophoresis assay, a new sensitive method as compared to electroimmuno assay |
| Q37096277 | Recent Advances in Lipoprotein Metabolism and the Genetic Dyslipoproteinemias |
| Q71878215 | Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome |
| Q73318670 | Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men |
| Q38752767 | Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study |
| Q38298100 | Sequence polymorphism in kringle IV 37 in linkage disequilibrium with the apolipoprotein (a) size polymorphism |
| Q78004675 | Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study |
| Q46415777 | Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation |
| Q74605470 | Serum concentration of lipoprotein(a) decreases on treatment with hydrosoluble coenzyme Q10 in patients with coronary artery disease: discovery of a new role |
| Q70079090 | Serum lipids and lipoproteins in patients with primary gout |
| Q36824175 | Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction |
| Q38807488 | Structure, function, and genetics of lipoprotein (a). |
| Q28297861 | The apolipoprotein(a) gene resides on human chromosome 6q26?27, in close proximity to the homologous gene for plasminogen |
| Q43641238 | The association of serum lipoprotein(a) levels, apolipoprotein(a) size and (TTTTA)(n) polymorphism with coronary heart disease. |
| Q39448830 | The cardiovascular safety of triphasic contraceptive steroids |
| Q67902600 | The effect of n-3 polyunsaturated fatty acids on Lp(a) |
| Q69292949 | The gene for the Lp(a)-specific glycoprotein is closely linked to the gene for plasminogen on chromosome 6 |
| Q71344128 | The localization of tissue factor and apolipoprotein(a) in atherosclerotic lesions of the human aorta and their relation to fibrinogen-fibrin transition |
| Q74397204 | The molecular markers of hemostatic activation on coronary artery disease |
| Q35196427 | Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. |
| Q71584188 | Thrombophilic factors in ischaemic and non-ischaemic idiopathic retinal vasculitis |
| Q51543579 | Type of diabetes and waist-hip ratio are important determinants of serum lipoprotein (a) levels in diabetic patients. |
| Q77341908 | Upregulated synthesis of both apolipoprotein A-I and apolipoprotein B in familial hyperalphalipoproteinemia and hyperbetalipoproteinemia |
| Q58071851 | Urinary apo(a) discriminates coronary artery disease patients from controls |
| Q58071785 | Urinary excretion of apolipoprotein(a) fragments in type 1 diabetes mellitus patients |
| Q58071705 | Urinary excretion of apolipoprotein(a): relation to other plasma proteins |
| Q47447593 | Variation in the size of human apolipoprotein(a) is due to a hypervariable region in the gene |
| Q57943731 | Vascular risk factors and lipoprotein(a) levels in the differential diagnosis of dementias |
| Q70431348 | [Apolipoproteinopathies] |
| Q67918676 | [Different levels of lipoprotein Lp(a) in adult diabetic patients depending on the therapeutic regimen] |
| Q73540801 | [Genetic risk factors for myocardial infarct] |
| Q51650561 | [The apolipoproteins in man ] |
| Q67979601 | [The mysteries of lipoprotein (a): a bridge between thrombosis and atheroma] |
Search more.